Find Paid Clinical Trials in Miami, Florida

Paid Clinical Trials and Focus Groups by Location

All Locations ... United States » ... Florida » ... Miami

Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: NN1250; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Trial of Percutaneous Endovascular Aneurysm Repair (PEVAR)

Condition: Abdominal Aortic Aneurysm
Interventions: Device: PEVAR (ProGlide closure); Device: SEVAR (IntuiTrak); Device: PEVAR (Prostar XL closure)
Sponsors: Endologix; Abbott Vascular
Not yet recruiting - verified February 2010
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcers
Interventions: Drug: MEBO Wound Ointment (MEBO); Drug: Sterile Saline Moistened Gauze
Sponsor: Skingenix, Inc.
Not yet recruiting - verified February 2010
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

Condition: Influenza
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Placebo comparator
Sponsor: Toyama Chemical Co., Ltd.
Recruiting - verified March 2010
Gender-Stratified Safety and Immunogenicity Study

Condition: Diarrhea
Interventions: Biological: Heat-Labile Enterotoxin of E. coli (LT); Biological: Placebo
Sponsor: Intercell USA, Inc.
Recruiting - verified February 2010
Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants

Conditions: Prematurity; Necrotizing Enterocolitis; Feeding Intolerance
Intervention: Procedure: Citrulline samples
Sponsor: University of Miami
Recruiting - verified February 2010
Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses

Condition: Cataract
Interventions: Device: Tecnis MF; Device: ReSTOR
Sponsor: Innovative Medical
Recruiting - verified February 2010
Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

Conditions: Vaginosis, Bacterial; Vaginal Infection
Interventions: Drug: GW05; Drug: GW05; Drug: GW05; Drug: Metronidazole
Sponsor: Graceway Pharmaceuticals, LLC
Recruiting - verified March 2010
A Dose-ranging Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler (DPI) and an HFA MDI

Condition: Asthma
Interventions: Drug: Albuterol DPI; Drug: Albuterol MDI; Drug: Placebo HFA MDI and Placebo DPI
Sponsor: Teva Global Respiratory Research LLC
Recruiting - verified February 2010
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified March 2010
Effects Of PF-04971729 In Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2; Adult
Interventions: Drug: 2 mg single dose; Drug: 2 mg split into twice daily; Drug: 4 mg single dose; Drug: 4 mg split into twice daily
Sponsor: Pfizer
Not yet recruiting - verified March 2010
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: sitagliptin
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: OPC-34712 + ADT; Drug: Placebo + ADT
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2010
To Assess the Long-term Safety, Efficacy and Tolerability of Inhaled Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: Placebo; Drug: FF Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Condition: Hypertriglyceridemia
Interventions: Drug: AMR101 (ethyl icosapentate); Drug: AMR101 (ethyl icosapentate); Drug: Placebo
Sponsor: Amarin Pharma Inc.
Recruiting - verified February 2010
To Assess the Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe, Stable COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Condition: Partial Epilepsy
Intervention: Drug: VX-765
Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting - verified February 2010
A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: PF-04937319
Sponsor: Pfizer
Recruiting - verified February 2010
Pharmacokinetics of MK4305 in Patients With Hepatic Insufficiency

Conditions: Insomnia; Hepatic Insufficiency
Intervention: Drug: MK4305
Sponsor: Merck
Recruiting - verified March 2010
Ridaforolimus in Patients With Hepatic Insufficiency

Conditions: Sarcoma; Hepatic Insufficiency
Intervention: Drug: ridaforolimus
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Disease-modifying antirheumatic drug
Sponsor: Pfizer
Recruiting - verified March 2010
Efficacy and Safety of EN3324 in Subjects With Chronic Low Back Pain

Condition: Chronic Low Back Pain
Interventions: Drug: EN3324; Drug: Placebo
Sponsor: Endo Pharmaceuticals
Recruiting - verified March 2010
A Study in Semagacestat for Alzheimer's Patients

Condition: Alzheimer's Disease
Intervention: Drug: Semagacestat
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus Type 2
Interventions: Drug: EGT0001442; Drug: Placebo capsules to match EGT0001442
Sponsor: Theracos
Recruiting - verified February 2010
Efficacy and Safety of TAK-491 and Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension.

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Condition: HIV Infections
Interventions: Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR); Drug: 3-4 commercially available antiretroviral drugs
Sponsor: Myriad Pharmaceuticals
Recruiting - verified March 2010
A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection

Condition: Cervical Intraepithelial Neoplasia
Interventions: Drug: RO5217790; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Long Term Safety Study of MK4305 in Patients With Primary Insomnia

Condition: Insomnia
Interventions: Drug: MK4305; Drug: Comparator: Placebo to MK4305
Sponsor: Merck
Recruiting - verified March 2010
Polysomnography Study of MK6096 in Patients With Primary Insomnia

Condition: Primary Insomnia
Interventions: Drug: MK6096 2.5 mg and placebo; Drug: Comparator: MK6096 5 mg and placebo; Drug: Comparator: MK6096 10 mg and placebo; Drug: Comparator: MK6096 20 mg and placebo
Sponsor: Merck
Recruiting - verified March 2010
A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID)for Knee Pain Due to Osteoarthritis

Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

Condition: Acne Vulgaris
Interventions: Drug: Tazarotene foam; Drug: Vehicle Foam
Sponsor: Stiefel, a GSK Company
Recruiting - verified February 2010
Safety and Efficacy of Paricalcitol Capsules in Decreasing High Serum Parathyroid Hormone Levels in Children 10-16 With Chronic Kidney Disease Stages 3 and 4

Condition: Chronic Kidney Disease Stage 3 and 4
Interventions: Drug: Zemplar (paricalcitol) Capsules; Drug: Placebo capsules
Sponsor: Abbott
Recruiting - verified December 2009
Study Evaluating Single Dose of ILV-095 in Psoriasis Subjects

Condition: Plaque Psoriasis
Interventions: Drug: ILV-095 300 mg in a 4 to 1 ratio; Drug: ILV-095 placebo 300 mg in a 4 to 1 ratio
Sponsor: Wyeth
Recruiting - verified March 2010
Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Condition: Onychomycosis
Interventions: Drug: IDP-108; Drug: Vehicle
Sponsor: Dow Pharmaceutical Sciences
Recruiting - verified March 2010
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875 6.25 mg; Drug: TAK-875 25 mg; Drug: TAK-875 50 mg; Drug: TAK-875 100 mg; Drug: TAK-875 200 mg; Drug: Glimepiride 2 mg or 4mg; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Condition: Abdominal Pain Upper
Interventions: Drug: REGN475/SAR164877; Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified February 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Condition: Leukemia-Lymphoma, Adult T-Cell
Intervention: Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
Sponsor: Washington University School of Medicine
Not yet recruiting - verified February 2010
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: flibanserin; Drug: placebo; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

Condition: Psoriasis
Interventions: Drug: Etanercept ONLY; Drug: Methotrexate and Etanercept
Sponsors: Amgen; Immunex Corporation
Recruiting - verified March 2010
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Linagliptin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip
Interventions: Other: Tanezumab 2.5 mg; Other: Tanezumab 5 mg; Other: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified February 2010
Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Condition: Restless Legs Syndrome
Interventions: Drug: pregabalin; Drug: placebo; Drug: pramipexole
Sponsor: Pfizer
Recruiting - verified February 2010
A Study To Access The Safety And Tolerability Of RN316 When Administered To Healthy Adult Subjects

Condition: Healthy Volunteers
Intervention: Biological: RN316
Sponsor: Pfizer
Recruiting - verified February 2010
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Condition: Coronary Artery Disease
Interventions: Drug: Apadenoson; Drug: Adenosine
Sponsors: PGxHealth, LLC; PPD
Recruiting - verified March 2010
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified March 2010
A Study of Tocilizumab in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis

Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: placebo; Drug: NSAIDs, corticosteroids, methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

Condition: Human Papillomavirus Infection
Interventions: Biological: V503; Biological: Comparator: Menactra™ (Concomitant); Biological: Comparator: Adacel™ (concomitant); Biological: Comparator: Menactra™ (Non-Concomitant); Biological: Comparator: Adacel™ (Non-concomitant)
Sponsor: Merck
Recruiting - verified March 2010
Sugammadex Hypersensitivity Study (Study P06042)

Condition: Hypersensitivity
Interventions: Drug: Sugammadex 4 mg/kg; Drug: Sugammadex 16 mg/kg; Drug: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Conditions: Hepatitis; Hepatitis C
Interventions: Drug: Filibuvir; Drug: Filibuvir; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Tanezumab in Osteoarthritis of the Hip or Knee

Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: oxycodone; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Matching placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified February 2010
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

Condition: Osteoarthritis, Knee
Interventions: Drug: PF-04457845; Drug: PF-04457845; Drug: Naproxen; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oxycodone User Registry (OUR)

Condition: Pain
Intervention: Drug: oxycodone immediate release (OXYRX)
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin glargine + preprandial lispro insulin; Biological: albiglutide + insulin glargine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Placebo; Drug: Hydrochlorothiazide
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified December 2009
TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Subjects With PHPT Unable to Undergo Parathyroidectomy

Condition: Hyperparathyroidism, Primary
Interventions: Drug: Placebo; Drug: cinacalcet HCl
Sponsor: Amgen
Not yet recruiting - verified March 2010
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Placebo; Drug: Dutogliptin
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
An Efficacy and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis (RA) Despite Treatment With Methotrexate, Non Steroidal Pain Medications and/or Corticosteroids

Condition: Arthritis, Rheumatoid
Interventions: Drug: placebo; Biological: golimumab; Biological: golimumab; Biological: golimumab
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

Condition: Osteoarthritis
Interventions: Biological: Tanezumab; Biological: Tanezumab; Other: Placebo
Sponsor: Pfizer
Not yet recruiting - verified February 2010
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: LY2216684
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant (MK0524A)) in Patients With Dyslipidemia

Condition: Dyslipidemia
Interventions: Drug: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: Extended-release niacin (ERN); Drug: Comparator: Placebo to ERN/LRPT
Sponsor: Merck
Recruiting - verified March 2010
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Condition: Pediculosis
Interventions: Drug: Malathion gel 0.5%; Drug: Permethrin 1% rinse (Nix Crème)
Sponsor: Taro Pharmaceuticals USA
Recruiting - verified March 2010
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: warfarin; Drug: placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Duke University
Recruiting - verified February 2010
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin; Drug: Alogliptin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Dutogliptin; Drug: Placebo
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
BIBW 2992 Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of LY2189102 in Patients With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: LY2189102; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327 10 mg; Other: Prednisone Placebo; Drug: PF-04171327 25 mg; Other: Prednisone Placebo; Drug: Prednisone 5 mg; Other: Placebo for PF-04171327; Other: Placebo; Other: Placebo for PF-04171327
Sponsor: Pfizer
Recruiting - verified March 2010
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

Conditions: Neoplasms; Unresectable Metastatic Cutaneous Melanoma
Intervention: Biological: Immunotherapeutic GSK2132231A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Abatacept Versus Adalimumab Head-to-Head

Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: linagliptin QD for 7 days
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Placebo; Drug: OROS MPH
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)

Condition: Degenerative Disc Disease
Interventions: Device: XL TDR; Other: Lumbar fusion surgery
Sponsor: NuVasive
Recruiting - verified February 2010
Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Condition: Adrenocortical Carcinoma (ACC)
Interventions: Drug: OSI-906; Other: Placebo
Sponsor: OSI Pharmaceuticals
Recruiting - verified December 2009
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LY2216684; Drug: Methylphenidate; Drug: Placebo (tablet); Drug: Placebo (capsule)
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Study to Evaluate 24 Hour Blood Sugar Control in Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared to Subjects Taking Metformin XR 1500 mg Uptitrated to Metformin XR 2000 mg

Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Metformin XR; Drug: Placebo matching Metformin 500 mg; Drug: Metformin XR; Drug: Placebo matching Saxagliptin 5 mg
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2010
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Study Evaluating Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in ErbB-2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

Condition: Venous Leg Ulcer
Interventions: Device: Dermagraft(R); Device: Profore
Sponsor: Advanced BioHealing, Inc.
Recruiting - verified February 2010
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Procedure: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified February 2010
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Condition: Colorectal Cancer
Intervention: Drug: olaparib
Sponsors: AstraZeneca; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified February 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effect of LY2062430 on the Progression of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effect of LY2062430 on the Progression of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Imatinib in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

Conditions: HIV Infections; Acquired Immunodeficiency Syndrome
Interventions: Drug: ATV/rtv 400/100mg; Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily; Drug: ATV/rtv 300/100mg; Drug: TDF 300mg
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.

Condition: Alzheimer Disease
Intervention: Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Randomized Withdrawal Study of Desvenlafaxine Succinate Sustained Release in Outpatients With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine succinate sustained release Dose A; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified February 2010
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

Condition: Diabetes Mellitus, Type 2
Intervention: Biological: CVX-096
Sponsor: Pfizer
Recruiting - verified March 2010
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Condition: Factor XIII Deficiency
Intervention: Biological: FXIII Concentrate Human
Sponsor: CSL Behring
Recruiting - verified March 2010
Efficacy and Safety Study of Subjects That Are Taking Saxagliptin Added Onto Metformin Immediate Release (IR), Twice Daily, Compared to Subjects Taking Metformin IR Alone

Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin plus metformin IR; Drug: Placebo plus metformin IR
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified October 2009
Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)

Condition: Coronary Artery Chronic Total Occlusion
Intervention: Device: Recanalization of a coronary chronic total occlusion
Sponsor: BridgePoint Medical
Recruiting - verified March 2010
Effects of Pregabalin (Lyrica) on Sleep Maintenance in Subjects With Fibromyalgia

Conditions: Fibromyalgia; Sleep Disorders
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Condition: Euvolemic Hyponatremia
Interventions: Drug: Lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified February 2010
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified February 2010
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Condition: Depression
Interventions: Drug: orvepitant; Other: placebo
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone in Post Menopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Bosutinib; Drug: Letrozole
Sponsor: Wyeth
Recruiting - verified March 2010
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
A Study of Tanezumab in Adults With Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 10 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 5 mg IV; Drug: Placebo for naproxen; Biological: Placebo for tanezumab; Drug: Naproxen; Biological: Placebo for tanezumab; Drug: Placebo for naproxen
Sponsor: Pfizer
Recruiting - verified February 2010
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: tetomilast; Drug: placebo
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2010
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633AM1)

Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Tanezumab and Nerve Function in Arthritis Patients

Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
A Study of the Safety and Efficacy of MK3577 in Patients With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK3577; Drug: Comparator: Placebo; Drug: MK3577; Drug: MK3577; Drug: Comparator: metformin
Sponsor: Merck
Recruiting - verified March 2010
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
PDE5 Inihibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsor: Bayer
Recruiting - verified March 2010
A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

Conditions: Actinic Keratoses; Skin Neoplasms
Interventions: Drug: Aminolevulinic Acid; Other: Vehicle
Sponsor: DUSA Pharmaceuticals, Inc.
Recruiting - verified March 2010
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Chemotherapy or Observation in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Tanezumab in Osteoarthritis of the Hip or Knee (2)

Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Condition: Alzheimer's Disease
Intervention: Drug: florbetapir F 18
Sponsor: Avid Radiopharmaceuticals
Recruiting - verified February 2010
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Condition: Optic Neuritis
Interventions: Drug: Glatiramer Acetate (Copaxone); Drug: placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified February 2010
Long Term Safety Study in Children and Adolescents With Attention Deficit Hyperactivity Disorder -Associated Insomnia

Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Intervention: Drug: eszopiclone
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With TMC114r (Ritonavir), and TMC125 (Etravirine) in HIV-1 Infected Pregnant Women

Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: TMC125 (etravirine); Drug: TMC114r (ritonavir)
Sponsors: Tibotec, Inc; Tibotec Therapeutics, a Division of Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: fluoxetine; Drug: duloxetine; Drug: duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

Conditions: Gastroparesis; Diabetic Gastroparesis; Diabetes; Diabetes Mellitus; Delayed Gastric Emptying
Interventions: Drug: metoclopramide; Drug: Placebo
Sponsor: Evoke Pharma
Recruiting - verified March 2010
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: duloxetine; Drug: Placebo; Drug: fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Efficacy and Safety of TAK-491 Combined With Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Chlorthalidone; Drug: Chlorthalidone; Drug: TAK-491; Drug: TAK-491; Drug: TAK-491
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

Condition: Head and Neck Cancer
Interventions: Drug: Tadalafil; Other: Placebo
Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2010
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Efficacy and Safety of Azilsartan Plus Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

Condition: Bipolar Depression
Interventions: Drug: Olanzapine Fluoxetine Combination; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Study of BMS-863233 in Patients With Hematologic Cancer

Condition: Refractory Hematologic Cancer
Interventions: Drug: Cdc7-inhibitor (BMS-863233); Drug: Cdc7-inhibitor (BMS-863233)
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified October 2009
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

Condition: Acute Decompensated Heart Failure
Intervention: Drug: CD-NP
Sponsor: Nile Therapeutics
Recruiting - verified March 2010
Phase III Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
NicVAX/Placebo as an Aid for Smoking Cessation

Conditions: Smoking Cessation; Smoking; Tobacco Cessation
Interventions: Biological: NicVAX vaccine; Biological: Placebo vaccine
Sponsors: Nabi Biopharmaceuticals; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Condition: Invasive Aspergillosis
Intervention: Drug: Voriconazole
Sponsor: Pfizer
Recruiting - verified February 2010
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition: Human Immunodeficiency Virus-1
Interventions: Drug: maraviroc; Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Tanezumab In Osteoarthritis Of The Knee (2)

Conditions: Arthritis; Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified February 2010
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsor: Pfizer
Recruiting - verified February 2010
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

Condition: HIV-1
Interventions: Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed
Sponsor: Pfizer
Recruiting - verified February 2010
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease

Condition: Alzheimer´s Disease
Interventions: Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Drug: Immune Globulin Intravenous (Human), 10% (IGIV, 10%); Other: Placebo solution
Sponsors: Baxter Healthcare Corporation; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.

Condition: Breast Cancer
Intervention: Device: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Sponsor: U-Systems, Inc.
Recruiting - verified February 2010
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

Conditions: Osteoarthritis; Arthritis
Interventions: Drug: NSAID; Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Drug: NSAID; Biological: tanezumab; Drug: NSAID
Sponsor: Pfizer
Recruiting - verified February 2010
Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone Immediate Release (IR) for Treatment of Acute Post-op Pain Following Elective Arthroscopic Shoulder Surgery

Condition: Postoperative Pain
Interventions: Drug: Oxycodone IR; Drug: Tapentadol IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Recruiting - verified February 2010
Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant Metastatic Colorectal Carcinoma

Condition: Metastatic Colorectal Cancer
Interventions: Biological: AMG 479; Other: Placebo; Other: FOLFIRI; Biological: AMG 655
Sponsor: Amgen
Recruiting - verified March 2010
Extension Study Of Tanezumab In Osteoarthritis

Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab
Sponsor: Pfizer
Recruiting - verified March 2010
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome.

Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: methotrexate; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Condition: Idiopathic Restless Legs Syndrome
Interventions: Drug: placebo and pregabalin; Drug: pramipexol; Drug: pramipexol; Drug: Pregabalin; Drug: pramipexol; Drug: pramipexol
Sponsor: Pfizer
Recruiting - verified March 2010
Study of Ataluren (PTC124™) in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Condition: Rheumatoid Arthritis
Interventions: Drug: infliximab; Drug: methotrexate; Drug: methylprednisolone; Drug: ocrelizumab; Drug: sham
Sponsor: Genentech
Recruiting - verified February 2010
Study of NNZ-2566 in Patients With Traumatic Brain Injury

Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsor: Neuren Pharmaceuticals Limited
Not yet recruiting - verified March 2010
A Phase 4, 6-Week, Randomized Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
SR-PAAS - Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: PAH; Pulmonary Arterial Hypertension; Pulmonary Hypertension; Sitaxsentan; ETRA
Interventions: Drug: Sitaxsentan; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified March 2010
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: RG1507; Drug: letrozole
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor.

Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Efficacy and Safety of RAD001 in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)

Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Conditions: Tuberous Sclerosis; Subependymal Giant Cell Astrocytoma
Interventions: Drug: Everolimus (RAD001); Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsor: Pfizer
Recruiting - verified February 2010
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

Condition: ADHD
Interventions: Drug: SPD489 (lisdexamfetamine dimesylate); Drug: Placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Condition: Pulmonary Fibrosis
Intervention: Drug: CNTO 888
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
Interventions: Drug: maraviroc; Drug: etravirine
Sponsor: Pfizer
Recruiting - verified March 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
PKUDOS: PKU Demographic, Outcomes, and Safety Registry

Conditions: Phenylketonuria; Hyperphenylalaninaemia
Intervention: Drug: Sapropterin Dihydrochloride
Sponsor: BioMarin Pharmaceutical
Recruiting - verified January 2010
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Conditions: Lupus Nephritis; Lupus Erythematosus, Systemic
Interventions: Drug: Abatacept; Drug: cyclophosphamide; Drug: azathioprine; Drug: prednisone; Drug: abatacept placebo; Drug: azathioprine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified February 2010
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been Previously Treated With Anti-TNF Therapy

Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: vorinostat (HDAC inhibitor); Drug: bortezomib; Drug: dexamethasone
Sponsor: Merck
Recruiting - verified February 2010
NINDS CRC Chronic Migraine Treatment Trial

Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Viral Shedding of MEDI-559 in Healthy 1 to <24 Month-Old Children

Condition: Healthy
Interventions: Biological: MEDI-559; Other: Placebo; Biological: MEDI-559
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

Condition: Back Pain
Interventions: Drug: placebo; Drug: tapentadol IR; Drug: oxycodone IR
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal GmbH
Not yet recruiting - verified February 2010
Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma

Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Paclitaxel and Trastuzumab and/or Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
(ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Condition: Acromegaly
Interventions: Drug: Octreotide Implant; Drug: Sandostatin LAR Depot
Sponsor: Endo Pharmaceuticals Solutions Inc.
Recruiting - verified February 2010
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo

Condition: Alzheimer's Disease
Interventions: Drug: LY450139; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis

Conditions: Candidemia; Candidiasis
Interventions: Drug: anidulafungin; Drug: fluconazole
Sponsor: Pfizer
Recruiting - verified March 2010
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Study of Losartan in Pediatric Patients With Hypertension

Condition: Hypertension
Interventions: Drug: Losartan 0.1 mg/kg/day titrating to a maximum dose of 1.4 mg/kg/day (not to exceed 100 mg/day) if blood pressure not at goal; Drug: Losartan 0.3 mg/kg/day titrating to a maximum dose of 1.4 mg/kg/day (not to exceed 100 mg/day) if blood pressure not at goal; Drug: Losartan 0.7 mg/kg/day titrating to a maximum dose of 1.4 mg/kg/day (not to exceed 100 mg/day) if blood pressure not at goal
Sponsor: Merck
Recruiting - verified February 2010
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: rhGAD65; Drug: rhGAD65; Drug: Placebo
Sponsor: Diamyd Therapeutics AB
Recruiting - verified March 2010
Tanezumab in Osteoarthritis Of The Hip

Conditions: Arthritis; Osteoarthritis; Osteoarthritis, Hip
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Biological: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: taspoglutide; Drug: placebo; Drug: pioglitazone; Drug: metformin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder

Condition: Major Depressive Disorder (MDD)
Intervention: Drug: repeat dose
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Follow-Up Study for Exubera

Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified March 2010
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents

Condition: Type 2 Diabetes
Intervention: Drug: sitagliptin phosphate
Sponsor: Merck
Recruiting - verified March 2010
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 0.1 mg/kg; Biological: PF-04360365 0.5 mg/kg; Biological: PF-04360365 1 mg/kg; Drug: Placebo; Biological: PF-04360365 3 mg/kg; Biological: PF-04360365 8.5 mg/kg
Sponsor: Pfizer
Recruiting - verified March 2010
A Phase 1 Dose Escalation Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Condition: Age-Related Macular Degeneration
Intervention: Drug: PF-04523655
Sponsors: Pfizer; Quark Pharmaceuticals
Recruiting - verified March 2010
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, or Osteosarcoma

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified February 2010
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Condition: Carcinoma, Hepatocellular
Interventions: Drug: sunitinib malate; Drug: sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified February 2010
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Evaluating Subcutaneous MOA-728 For Treatment of Opioid-Induced Constipation in Patients With Advanced Illness

Condition: Opioid-induced Constipation
Interventions: Drug: Methylnaltrexone bromide (MOA-728); Drug: Placebo
Sponsors: Wyeth; Progenics Pharmaceuticals, Inc.
Recruiting - verified February 2010
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma

Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Drug: Adriamycin; Drug: Bleomycin; Drug: Vinblastine; Drug: Dacarbazine
Sponsors: M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2010
Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study

Condition: Atrial Septal Defect
Intervention: Device: AMPLATZER Septal Occluder
Sponsor: AGA Medical Corporation
Recruiting - verified January 2009
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in People With Idiopathic Pulmonary Fibrosis

Condition: Pulmonary Fibrosis
Interventions: Drug: Prednisone; Drug: Azathioprine; Drug: N-acetylcysteine (NAC); Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
LENS - Long-term Eltrombopag Observational Study

Condition: Ocular Safety
Intervention: Drug: Observational Study
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Defibrotide for Patients With Hepatic VOD: A Treatment IND Study

Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsor: Gentium SpA
Recruiting - verified February 2010
Study of Ambrisentan and Phosphodiesterase Type-5 Inhibitor (PDE-5i) to Treat Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: ambrisentan plus sildenafil or tadalafil
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Condition: Head and Neck Cancer
Interventions: Biological: IMC-A12; Biological: cetuximab
Sponsor: ImClone LLC
Recruiting - verified March 2010
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Phase 2 Study of Enzastaurin With 5 FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

Condition: Colorectal Cancer
Interventions: Drug: Enzastaurin; Drug: Placebo; Drug: Leucovorin; Drug: 5-FU; Drug: Bevacizumab
Sponsors: Eli Lilly and Company; Roche Pharma AG
Recruiting - verified February 2010
The Vascutek AnacondaTM Stent Graft System Phase II IDE Study

Condition: Infrarenal Abdominal Aortic Aneurysm
Intervention: Device: Anaconda Stent Graft System
Sponsors: Terumo CVS; Vascutek Ltd., Scotland
Recruiting - verified March 2010
A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
Interventions: Biological: infliximab; Drug: conventional systemic agents; Biological: Biological therapies other than infliximab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Conditions: HIV Infections; Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent human papillomavirus vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified June 2009
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Biological: IMMU-107 (hPAM4)
Sponsor: Immunomedics, Inc.
Recruiting - verified February 2010
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

Condition: Epilepsy
Intervention: Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified March 2010
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of the Safety and Effectiveness of Doripenem Compared With Imipenem in the Treatment of Patients With Ventilator-associated Pneumonia

Conditions: Pneumonia; Pneumonia, Bacterial
Interventions: Drug: doripenem; Drug: imipenem/cilastatin
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

Condition: Hyponatremia
Interventions: Drug: lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified February 2010
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Vaccine Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Recruiting - verified February 2010
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: PF-04494700; Drug: PF-04494700; Drug: Placebo
Sponsors: Pfizer; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

Condition: Aneurysmal Subarachnoid Hemorrhage
Interventions: Drug: clazosentan; Drug: placebo
Sponsor: Actelion
Recruiting - verified February 2010
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
VA NEPHRON-D: Diabetes iN Nephropathy Study

Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Prazosin and Combat Trauma PTSD

Conditions: PTSD; Sleep Disorders
Interventions: Drug: prazosin; Other: placebo
Sponsor: Department of Veterans Affairs
Recruiting - verified January 2010
Phase II Trial of Capecitabine in Combination With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: fulvestrant
Sponsors: Accelerated Community Oncology Research Network; Hoffmann-La Roche; AstraZeneca
Recruiting - verified February 2010
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Condition: Aspergillosis
Interventions: Drug: voriconazole; Drug: anidulafungin; Drug: voriconazole
Sponsors: Pfizer; Mycoses Study Group
Recruiting - verified February 2010
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

Condition: Epilepsies, Partial
Interventions: Drug: pregabalin 600 mg/day; Drug: pregabalin 150 mg/day
Sponsor: Pfizer
Recruiting - verified March 2010
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

Condition: Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Rotigotine; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Condition: Epilepsy
Interventions: Drug: lacosamide; Drug: lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
A Study of Staphylococcus Aureus Vaccine (V710) in Patients Scheduled for Cardiothoracic Surgery

Conditions: Staphylococcus Aureus; Bacteremia; Mediastinitis
Interventions: Biological: V710; Biological: Comparator: Placebo (unspecified)
Sponsor: Merck
Recruiting - verified March 2010
Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Drug: conventional systemic agents; Biological: infliximab; Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Randomized Phase 3b Study in Previously Untreated Multiple Myeloma Patients: VELCADE,Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone

Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition: Moderate Risk of CVD
Interventions: Drug: Aspirin (Acetylsalicylic acid, BAYE4465); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
An Observational Study of the Ethnic Impact of Patients Undergoing 2nd Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

Condition: Lung Neoplasms
Intervention: Drug: Pemetrexed
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

Conditions: Candidiasis; Candida
Intervention: Drug: anidulafungin
Sponsor: Pfizer
Recruiting - verified March 2010
Early Initiation of HAART

Condition: HIV Infections
Interventions: Procedure: Early Initiation of Highly Active Anti-Retroviral Therapy; Procedure: Standard Care
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified February 2010
Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Conditions: Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: duloxetine hydrochloride; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014179)

Condition: Ulcerative Colitis
Interventions: Biological: golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014176)

Condition: Ulcerative Colitis
Interventions: Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents

Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2009
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Condition: Heart Decompensation
Interventions: Drug: Placebo; Drug: Nesiritide
Sponsor: Scios, Inc.
Recruiting - verified February 2010
Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

Condition: Pain, Postoperative
Interventions: Drug: pregabalin (Lyrica); Drug: pregabalin (Lyrica); Drug: matched placebo
Sponsor: Pfizer
Recruiting - verified February 2010
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
L-Arginine Supplements in Treating Women Who Are Cancer Survivors

Conditions: Cancer Survivor; Sexual Dysfunction and Infertility; Sexuality and Reproductive Issues; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: L-arginine/Korean ginseng/ Gingko biloba/damiana-based supplement; Other: placebo
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified July 2009
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Conditions: Venous Thrombosis; Pulmonary Embolism
Interventions: Drug: Apixaban; Drug: Enoxaparin
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Condition: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Interventions: Drug: cisplatin + Docetaxel; Drug: Panitumumab
Sponsor: Amgen
Recruiting - verified March 2010
Sunitinib, Cisplatin or Carboplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation

Condition: Pulmonary Embolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease

Conditions: Anemia; Chronic Kidney Disease; Kidney Disease
Interventions: Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2W
Sponsor: Amgen
Recruiting - verified March 2010
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Combination Therapy in Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: bosentan; Drug: bosentan and sildenafil combination
Sponsor: Actelion
Recruiting - verified February 2010
Expanded Access Program for Maraviroc At Multiple Centers

Condition: HIV Infections
Intervention: Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified February 2010
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Condition: Lung Cancer
Intervention: Drug: IPI-504
Sponsor: Infinity Pharmaceuticals
Recruiting - verified February 2010
The PACE-MI Registry Study

Condition: Myocardial Infarction
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer

Condition: Lung Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Telephone Interactive System; Other: Blood Samples
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Metastatic Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: FOLFIRI - Panitumumab; Drug: FOLFIRI - Bevacizumab
Sponsor: Amgen
Recruiting - verified February 2010
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Biological: Stimuvax; Biological: Placebo
Sponsor: EMD Serono
Recruiting - verified February 2010
A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

Conditions: Neuralgia; Spinal Cord Injuries
Interventions: Drug: placebo; Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified March 2010
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)

Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Prolieve® Thermodilatation System
Sponsor: Boston Scientific Corporation
Recruiting - verified February 2010
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effect of Prolonged Electrical Stimulation on Neural Plasticity in Spinal Cord Injury

Condition: Spinal Cord Injury
Intervention: Behavioral: Somatosensory Stimulation and Massed Practice Training
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Conditions: Graft Versus Host Disease; Leukemia
Interventions: Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.

Condition: Lupus Nephritis
Interventions: Drug: mycophenolate mofetil [CellCept]; Drug: Cyclophosphamide; Drug: mycophenolate mofetil [CellCept]; Drug: Azathioprine
Sponsors: Hoffmann-La Roche; Aspreva Pharmaceuticals
Recruiting - verified February 2010
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

Condition: Hepatitis B Infection
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: zoledronic acid; Radiation: samarium Sm 153 lexidronam pentasodium; Radiation: strontium chloride Sr 89
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.

Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Visual Field Assessment With Subjects Who Receive Either Lyrica Or Sugar Pills

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
EXTEND (Eltrombopag Extended Dosing Study)

Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: eltrombopag olamine (SB-497115-GR)
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Clinical Trial Ceftriaxone in Subjects With ALS

Conditions: Amyotrophic Lateral Sclerosis; ALS
Interventions: Drug: ceftriaxone; Other: placebo
Sponsors: Massachusetts General Hospital; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Conditions: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; The Cleveland Clinic
Recruiting - verified February 2010
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery

Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
A Study on the Effectiveness and Safety of Diazepam Injection (Vanquix™) for Patients With Epilepsy That Receive Antiepileptic Drugs, But Still Experience Acute Repetitive Seizures (Bouts or Clusters of Seizures) That Require Treatment

Conditions: Epilepsy; Epilepsy, Generalized; Epilepsy, Complex Partial; Epilepsies, Partial; Seizures
Interventions: Drug: Diazepam; Drug: Placebo
Sponsor: King Pharmaceuticals Research and Development
Recruiting - verified March 2010
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Conditions: Head and Neck Cancer; Radiation Toxicity
Interventions: Drug: amifostine trihydrate; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

Condition: Leukemia
Interventions: Behavioral: compliance monitoring; Drug: mercaptopurine; Drug: methotrexate; Other: study of socioeconomic and demographic variables
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole
Sponsors: American College of Surgeons; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Radiation Therapy in Treating Young Patients With Gliomas

Condition: Brain and Central Nervous System Tumors
Intervention: Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: atrasentan hydrochloride; Drug: docetaxel; Drug: prednisone; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: quality-of-life assessment
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin's Disease

Condition: Lymphoma
Interventions: Drug: CHOP regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate the Efficacy of Xolair in Atopic Asthmatics

Condition: Asthma
Interventions: Drug: omalizumab; Drug: placebo
Sponsor: Genentech
Recruiting - verified February 2010
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: lomustine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Nosocomial Pneumonia With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Condition: Pneumonia, Staphylococcal
Interventions: Drug: linezolid; Drug: vancomycin
Sponsor: Pfizer
Recruiting - verified February 2010
Study of Late-Occurring Complications in Childhood Cancer Survivors

Condition: Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: questionnaire administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment

Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsor: Boehringer Ingelheim Pharmaceuticals
Available - verified March 2010
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: cisplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

Conditions: Leukemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cyclophosphamide and Doxorubicin or Paclitaxel in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: therapeutic immune globulin; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010

Find Paid Clinical Trials in Miami, Florida - Clinical Trials

Find Paid Clinical Trials in Miami, Florida

Paid Clinical Trials and Focus Groups by Location

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials